2,3-bis(palmitoyloxy)-2-propyl-1-palmitoylcysteine has been researched along with Crohn Disease in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Adema, GJ; de Jong, DJ; Drenth, JP; Ferwerda, G; Girardin, SE; Jacobs, L; Jansen, T; Kramer, M; Kullberg, BJ; Naber, TH; Netea, MG; Van der Meer, JW | 1 |
1 other study(ies) available for 2,3-bis(palmitoyloxy)-2-propyl-1-palmitoylcysteine and Crohn Disease
Article | Year |
---|---|
Nucleotide-binding oligomerization domain-2 modulates specific TLR pathways for the induction of cytokine release.
Topics: Acetylmuramyl-Alanyl-Isoglutamine; Adjuvants, Immunologic; Animals; Cells, Cultured; Crohn Disease; Cysteine; Cytokines; Drug Synergism; Humans; Intracellular Signaling Peptides and Proteins; Lipopeptides; Lipoproteins; Macrophages, Peritoneal; Membrane Glycoproteins; Mice; Mice, Inbred C57BL; Mice, Knockout; Mycoplasma; Nod2 Signaling Adaptor Protein; Oligopeptides; Peptidoglycan; Receptors, Cell Surface; Receptors, Immunologic; Signal Transduction; Toll-Like Receptor 2; Toll-Like Receptor 3; Toll-Like Receptor 4; Toll-Like Receptor 5; Toll-Like Receptor 7; Toll-Like Receptor 9; Toll-Like Receptors | 2005 |